Inositec AG

Swiss Biotech Association

Member

Inositec AG is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune™ platform of inositol phosphate (IP6) analogs. The company’s lead programs address vascular and renal calcification disorders, including orphan indications. The company's current focus is on developing the cardiovascular calcification inhibitor INS-3001 as a first-in-class treatment for aortic valve stenosis. Inositec was founded in December 2015 as a spin-off of ETH Zurich.

Location

Technoparkstrasse 1, 8005 Zürich, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2015
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Rowestil Consulting GmbH

Expertise in exploratory clinical drug/diagnostic development is available across a number of disease areas. Timing of input into the developmental strategy from regulatory and commercial perspectives is important in moving development programs towards success.
6318 Walchwil

Member

Sintetica SA

Sintetica is a pharmaceutical company delivering injectable medicines to patients worldwide, through innovative science and excellence in development, production and marketing. The multicultural high-performing organization is built to support both the national growth and the global expansion.
6850 Mendrisio

Member

Quercis Pharma AG

Quercis Pharma AG is a private Swiss biotech company advancing a novel antithrombotic in multiple indications: the lead program is prevention of Venous Thrombosis Embolism in advanced cancer patients (phase III) followed by clinical trials in Sickle Cell Disease (phase II) and Covid-19 (phase II).
6300 Zug

Member